Alvotech and stada increase access to adalimumab for patients in switzerland with the launch of hukyndra®

Reykjavik, iceland and bad vilbel, germany, sept. 22, 2022 (globe newswire) -- alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and stada arzneimittel ag (stada), announced today the launch of hukyndra®, a high-concentration, low-volume, citrate-free formulation, biosimilar to humira® (adalimumab), in switzerland.
ALVO Ratings Summary
ALVO Quant Ranking